1. Scrip
  2. >>Therapy Areas
  3. >>Cardiovascular

Sorbent's lead heart failure product shows Phase II promise

 
• By Alexandra Shimmings

The private US biopharmaceutical company Sorbent Therapeutics has presented promising Phase II data for its lead drug candidate, CLP1001, at a late-breaking clinical trials session at the ESC Heart Failure Congress in Belgrade, Serbia.

The private US biopharmaceutical company Sorbent Therapeutics has presented promising Phase II data for its lead drug candidate, CLP1001, at a late-breaking clinical trials session at the ESC Heart Failure Congress in Belgrade, Serbia.

The non-absorbed cross-linked polyelectrolyte polymer is designed to remove potassium, sodium and fluid from the gastrointestinal tract to reduce fluid...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Cardiovascular

Novartis Upbeat Even With Entresto Expiry Looming

 
• By Kevin Grogan

Swiss major confident that new oncology drugs will fill revenue gap.

AstraZeneca’s Amyloidosis Drug Fails In Phase III But Subgroup Hopes Persist

 
• By Andrew McConaghie

Anselamimab was expected to complement Alexion's portfolio of amyloid therapies, but regulators will have to be convinced of its benefits to a patient subgroup in the CARES trial.

Bayer’s Kerendia Gains Blockbuster Indication For Heart Failure

 
• By Joseph Haas

New US approval in heart failure with preserved or mildly reduced ejection fraction should add to Kerendia’s earning power on top of chronic kidney disease indication.

Phase III Success For AstraZeneca’s $5bn Hypertension Hope Baxdrostat

 
• By Andrew McConaghie

Rivals Mineralys could be first to file but AstraZeneca is banking on its cardiovascular market know-how to lead the emerging class.

More from Therapy Areas

Hopes Rise For Sickle Cell Gene Therapy Access As 33 States Join CMS Program

 
• By Alaric DeArment

CMS said that 33 US states plus the District of Columbia and Puerto Rico had joined a program whereby the agency negotiates outcomes-based contracts on their behalf.

AstraZeneca’s Amyloidosis Drug Fails In Phase III But Subgroup Hopes Persist

 
• By Andrew McConaghie

Anselamimab was expected to complement Alexion's portfolio of amyloid therapies, but regulators will have to be convinced of its benefits to a patient subgroup in the CARES trial.

PureTech Ponders Way Forward As CEO Exits

 
• By Kevin Grogan

Bharatt Chowrira departs days after firm’s chair stepped down.